Clinical Trials Using Pembrolizumab

Clinical trials are research studies that involve people. The clinical trials on this list are studying Pembrolizumab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 76-100 of 500

  • Lenvatinib and Pembrolizumab for the Treatment of Recurrent or Metastatic Adenoid Cystic Carcinoma or Other Salivary Gland Cancers

    This phase II trial studies how well lenvatinib and pembrolizumab work in treating patients with adenoid cystic carcinoma or other salivary gland cancers that have come back (recurrent) or have spread to other places in the body (metastatic). Lenvatinib works by blocking receptor tyrosine kinases, proteins that help cells grow and develop blood vessels. Blocking these proteins may slow the growth of cancer cells and cut off the blood supply that feeds them. Pembrolizumab blocks a protein, PD-1, that acts as a “brake” on the immune system. Blocking this protein is like releasing the brakes; it frees the immune system to target and kill cancer cells. Giving lenvatinib and pembrolizumab may work better in slowing and stopping the growth of adenoid cystic carcinoma or other salivary gland cancers compared to lenvatinib or pembrolizumab alone.
    Location: 8 locations

  • Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    The purpose of study is to evaluate if the addition of GSK3359609 to pembrolizumab as first-line treatment improves the efficacy of pembrolizumab in participants with recurrent or metastatic (R / M) head and neck squamous cell carcinoma / cancer (HNSCC). This is a randomized, double-blind, adaptive Phase II / III study comparing a combination of GSK3359609 inducible T cell co-stimulatory receptor (ICOS) agonist and pembrolizumab to pembrolizumab plus placebo in participants with programmed death receptor 1-ligand 1 (PD-L1) combined positive score (CPS) >=1 R / M HNSCC. Approximately 600 participants will be enrolled in the study and will have a follow-up until death.
    Location: 10 locations

  • RPTR-147 in Patients With Selected Solid Tumors and Lymphomas

    The purpose of this study is to assess the safety and tolerability of escalating doses of RPTR-147 as a monotherapy and in combination with Pembrolizumab in patients with selected solid tumors and lymphomas.
    Location: 8 locations

  • Pembrolizumab in Treating Patients with Untreated Nasal Type Extranodal NK / T-Cell Lymphoma

    This phase II trial studies how well pembrolizumab works in treating patients with nasal type extranodal natural killer (NK) / T-cell lymphoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 10 locations

  • Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676 / KEYNOTE-676)

    This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with BCG, compared to BCG monotherapy, in participants with HR NMIBC that is either persistent or recurrent following adequate BCG induction (Cohort A), or that is naïve to BCG treatment (Cohort B). The primary hypothesis for Cohort A is that the combination of pembrolizumab plus BCG has a superior complete response rate (CRR) as assessed by central pathology review compared to BCG in participants with carcinoma in situ (CIS). The primary hypothesis for Cohort B is that the combination of pembrolizumab plus BCG (either reduced maintenance or full maintenance) has a superior Event Free Survival (EFS) compared to BCG.
    Location: 8 locations

  • Second-Line Pembrolizumab in Combination with Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma

    This phase II trial studies the side effects and how well pembrolizumab in combination with gemcitabine, vinorelbine, and pegylated liposomal doxorubicin hydrochloride work in treating patients with Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as gemcitabine, vinorelbine, and pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab, gemcitabine, vinorelbine, and pegylated liposomal doxorubicin hydrochloride may work better at treating Hodgkin lymphoma.
    Location: 8 locations

  • Pembrolizumab / Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811 / KEYNOTE-811)

    The study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trastuzumab in combination with SOC chemotherapy in participants with HER2-positive gastric cancer. The primary hypotheses of the study are that pembrolizumab plus trastuzumab in combination with chemotherapy is superior to trastuzumab plus chemotherapy in terms of 1) progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR), and 2) overall survival (OS).
    Location: 8 locations

  • Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer

    This is an international, multi-center, open-label, phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 / PD-L1 based immunotherapy. At least 321 patients are anticipated to be enrolled across approximately 40 sites from North America and Europe.
    Location: 12 locations

  • A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495 / KEYNOTE-495)

    This study will investigate the utility of biomarker-based triage for study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic therapy. Study participants within groups defined by a biomarker-based classifier (gene expression profile [GEP] and tumor mutational burden [TMB]) will be randomized to receive pembrolizumab in combination with quavonlimab (MK-1308), MK-4280, or lenvatinib. The primary hypotheses are as follows: In participants receiving pembrolizumab in combination with either quavonlimab, MK-4280, or lenvatinib, the Objective Response Rate (ORR) will be 1) greater than 5% among participants with low GEP and low TMB, 2) greater than 20% among participants with low GEP and high TMB, 3) greater than 20% among participants with high GEP and low TMB, and 4) greater than 45% among participants with high GEP and high TMB.
    Location: 12 locations

  • Pembrolizumab and Involved Site Radiation Therapy in Treating Patients with Early Stage Relapsed or Refractory Hodgkin Lymphoma

    This phase II trial studies how well pembrolizumab and involved site radiation therapy works in treating patients with early stage Hodgkin lymphoma that has come back after a period of improvement (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Involved site radiotherapy is a more targeted form of radiation therapy which uses imaging studies such as computerized tomography and positron emission tomography scans to limit the dose and field of radiation administered in order to limit undesirable side effects. Giving pembrolizumab and involved site radiation therapy may improve the ability of T cells to recognize and fight off cancer cells.
    Location: 8 locations

  • Carboplatin with or without Pembrolizumab in Treating Patients with Advanced Breast Cancer with Locally Recurrent Chest Wall Disease That Cannot Be Removed by Surgery

    This randomized phase II trial studies how well carboplatin with or without pembrolizumab work in treating patients with breast cancer that has spread to other places in the body (advanced) with chest wall disease that has come back (locally recurrent) and cannot be removed by surgery. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 9 locations

  • Pembrolizumab and Recombinant Interleukin-12 in Treating Patients with Solid Tumors

    This phase I trial studies the side effects and best dose of pembrolizumab and recombinant interleukin-12 in treating patients with solid tumors. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Recombinant interleukin-12 may kill tumor cells by blocking blood flow to the tumor and by stimulating white blood cells to kill tumor cells. Giving pembrolizumab and recombinant interleukin-12 may work better than giving pembrolizumab alone in treating patients with solid tumors.
    Location: 10 locations

  • A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors

    To better understand the safety and tolerability of ALKS 4230 in humans
    Location: 9 locations

  • Pembrolizumab in Treating Patients with HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms

    This phase I trial studies the side effects of pembrolizumab in treating patients with human immunodeficiency virus (HIV) and malignant neoplasms that have come back (relapsed), do not respond to treatment (refractory), or have distributed over a large area in the body (disseminated). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 10 locations

  • Pembrolizumab in Treating Younger Patients with Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

    This phase I trial studies the side effects and best dose of pembrolizumab and to see how well it works in treating younger patients with high-grade gliomas (brain tumors that are generally expected to be fast growing and aggressive), diffuse intrinsic pontine gliomas (brain stem tumors), brain tumors with a high number of genetic mutations, ependymoma or medulloblastoma that have come back (recurrent), progressed, or have not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may induce changes in the body's immune system, and may interfere with the ability of tumor cells to grow and spread.
    Location: 11 locations

  • Lenvatinib and Pembrolizumab in People with Advanced Soft Tissue Sarcoma

    This phase II trial studies the effect of the combination of lenvatinib and pembrolizumab and how well it works in treating patients with soft tissue sarcomas that has spread to other places in the body (metastatic) and cannot be removed by surgery. Lenvatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving lenvatinib together with pembrolizumab together may kill more tumor cells.
    Location: 7 locations

  • Pembrolizumab and Ablative Radiotherapy with or without Olaparib for the Treatment of Metastatic Triple-Negative Breast Cancer

    This phase II trial studies the effect of pembrolizumab, ablative radiotherapy with or without olaparib in treating patients with triple-negative breast cancer that has spread to other places of the body (metastatic). Pembrolizumab is an antibody, like the proteins made by the immune system to protect the body from harm. Pembrolizumab blocks the protein PD 1 (programmed cell death receptor 1) that usually acts as a “brake” on the immune system. Blocking this protein is like releasing the brakes, so that the immune system can target tumor cells and destroy them. Stereotactic ablative radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Olaparib is a type of medication called a PARP inhibitor. PARP is a protein that helps repair damage to deoxyribonucleic acid (DNA), the genetic material that serves as your body’s instruction book. Changes (mutations) in DNA can cause tumor cells to grow quickly and out of control. But PARP inhibitors have been shown to prevent PARP from working, so tumor cells can’t repair themselves, and they stop growing. The combination of radiation with pembrolizumab or radiation with pembrolizumab and olaparib may activate the body’s immune cells to travel to and attack and destroy other sites of triple-negative breast cancer in the body.
    Location: 7 locations

  • Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and / or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

    ONCR-177-101 is a phase 1, open-label, multi-center, dose escalation and expansion study of ONCR-177, an oncolytic Herpes Simplex Virus for intratumoral injection, alone and in combination with PD-1 blockade in adult subjects with advanced and / or refractory cutaneous, subcutaneous or metastatic nodal solid tumors or with Liver Metastases of Solid Tumors. The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
    Location: 8 locations

  • A Study of Pembrolizumab plus Local Chemotherapy using Isolated Limb Infusion (ILI) for Patients with Sarcoma in the Arm or Leg

    This phase II trial studies how well pembrolizumab and chemotherapy delivered via isolated limb infusion works in treating patients with sarcoma of the arm or leg that has spread to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as melphalan and dactinomycin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Isolated limb infusion delivers chemotherapy to the affected arm or leg. Giving pembrolizumab and isolated limb infusion with melphalan and dactinomycin into the affected arm or leg may delay the time before the disease gets worse (progresses).
    Location: 7 locations

  • Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18 / KEYNOTE-A18 / ENGOT-cx11 / GOG-3047)

    The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer. The primary hypotheses are that pembrolizumab plus concurrent chemoradiotherapy is superior to placebo plus concurrent chemoradiotherapy with respect to progression-free survival and overall survival. Once the study objectives have been met or the study has ended, participants will be discontinued from this study and will be enrolled in an extension study to continue protocol-defined assessments and treatment.
    Location: 10 locations

  • BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination with Intensive Chemotherapy as Frontline Therapy in Patients with Acute Myeloid Leukemia

    This phase II trial studies how well cytarabine and idarubicin or daunorubicin with or without pembrolizumab work in treating patients with newly-diagnosed acute myeloid leukemia. Drugs used in chemotherapy, such as cytarabine, idarubicin, and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving induction chemotherapy with pembrolizumab may work better than induction chemotherapy alone in treating patients with acute myeloid leukemia.
    Location: 7 locations

  • Study of DF1001 in Patients With Advanced Solid Tumors

    DF1001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express human epidermal growth factor receptor 2 (HER2). Two combination therapy cohorts will be opened for enrollment, DF1001 + nivolumab and DF1001 + Nab paclitaxel. The second phase will include a dose expansion using the best dose selected from the first phase of the study. Multiple cohorts will be opened with eligible patients having either selected solid tumors, or solid tumors expressing high levels of HER2.
    Location: 10 locations

  • Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641 / KEYNOTE-641)

    The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and enzalutamide in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy for mCRPC, are abiraterone-naïve, or are intolerant to or progressed on abiraterone acetate. There are two primary study hypotheses. Hypothesis 1: The combination of pembrolizumab plus enzalutamide is superior to placebo plus enzalutamide with respect to Overall Survival (OS). Hypothesis 2: The combination of pembrolizumab plus enzalutamide is superior to placebo plus enzalutamide with respect to Radiographic Progression-free Survival (rPFS) per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review.
    Location: 7 locations

  • Study of Pembrolizumab Following Surgery in Patients with High Number of Genetic Changes (Microsatellite Instability High) Solid Tumors

    This phase II trial studies how well pembrolizumab works in treating patients with microsatellite instability-high (MSI-H) circulating tumor deoxyribonucleic acid (ctDNA) positive solid tumors after surgery. MSI-H tumor cells have a greater than normal number of genetic markers called microsatellites. Microsatellites are short, repeated, sequences of DNA. Cancer cells that have large numbers of microsatellites may have defects in the ability to correct mistakes that occur when DNA is copied in the cell. These MSI-H cancer cells may be circulating in patients’ blood. An investigational blood test will show if residual tumor cells are present in the blood even though tumor was removed. Having ctDNA in the blood may increase the risk of cancer coming back after surgical removal of tumor. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial studies if the study drug, pembrolizumab, can remove leftover tumor cells in the blood and prevent cancer from coming back after tumor was surgically removed.
    Location: 7 locations

  • A Study of ASP1951 in Subjects With Advanced Solid Tumors

    The primary purpose of this study is to evaluate the tolerability and safety profile of ASP1951 when administered as a single agent and in combination with pembrolizumab in participants with locally advanced (unresectable) or metastatic solid tumors; characterize the pharmacokinetic profile of ASP1951 when administered as a single agent and in combination with pembrolizumab; and determine the recommended phase 2 dose (RP2D) of ASP1951 and / or maximum tolerated dose (MTD) when administered as a single agent and in combination with pembrolizumab. This study will also evaluate the anti-tumor effect of ASP1951 when administered as a single agent and in combination with pembrolizumab.
    Location: 8 locations